BENICIA, Calif., Oct. 22 /PRNewswire/ -- AcroMetrix, the leading
provider of quality control standards for clinical diagnostic and blood
testing laboratories, announced that they have enhanced their OptiQuant
HIV-1 Quantification Panel to be the first to utilize an EDTA-based normal
human plasma matrix. This product is for Research Use Only, not for use in
This new matrix, called OptiMatrix, allows the OptiQuant HIV-1 panel to
most closely mimic a patient sample. The commutability of the OptiQuant HIV
panel ensures accurate comparison and compatibility between a wide variety
of testing platforms globally. As a further improvement, AcroMetrix panel
members are the first to be directly traceable to International Units per
milliliter (IU/mL) to facilitate global quality through ISO standards.
"The OptiQuant HIV-1 Quantification Panel represents our commitment to
standardization in diagnostics," said Michael J. Eck, President and CEO.
"The new OptiQuant panel is the first HIV validation panel available to be
traceable to the WHO standard, in a truly commutable matrix."
This new OptiQuant HIV Panel fully complies with the ISO 17511:2003 (In
vitro diagnostic medical devices -- Measurement of quantities in biological
samples -- Metrological traceability of values assigned to calibrators and
control materials) standard. Through the ISO 17511 standard, AcroMetrix
aims to facilitate a uniform global quality control network by producing
consistent and traceable universal standards.
"Our goal is to standardize diagnostic testing so that a patient can
receive a truly comparable test result regardless of the doctor or
laboratory they choose to visit," said Mr. Eck, "The new OptiQuant HIV
panel is a step in that direction for HIV viral load testing."
AcroMetrix, with facilities in Benicia, California and Alkmaar, the
Netherlands, provides a comprehensive line of molecular and serological
diagnostic quality control products that assist laboratories in meeting
current government regulations regarding quality. AcroMetrix maintains this
leadership role by consistently developing innovative standards, external
run controls, and validation kits for molecular and serological testing in
blood screening and clinical diagnostic laboratories. For more information
on AcroMetrix please visit the company web site at